Brought to you by 
Novartis spins off Alcon eye care unit as independent company in deal worth up to $5bn
28 May 2019
Executive Summary
After considering various other options, Novartis AG decided to spin off the device-focused parts of its Alcon Inc. eye care division into a separate independent company so the former can focus on its pharma business.
Deal Industry
- Medical Devices
-
Medical Devices
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Divestiture/Spin-Out
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis spins off Alcon eye care unit as independent company in deal worth up to $5bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice